VCRE (Vicore Pharma Holding AB) PS Ratio: (As of Jul. 07, 2026)


VCRE Vicore Pharma Holding AB VCRE
13 GF Score
Price $15.03
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Vicore Pharma Holding AB's share price is $15.025. Vicore Pharma Holding AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Hence, Vicore Pharma Holding AB's PS Ratio for today is .

Warning Sign:

Vicore Pharma Holding AB stock PS Ratio (=964.29) is close to 2-year high of 964.29.

The historical rank and industry rank for Vicore Pharma Holding AB's PS Ratio or its related term are showing as below:

VCRE' s PS Ratio Range Over the Past 10 Years
Min: 7.47   Med: 1171.04   Max: 36583.78
Current: 891.58

During the past 13 years, Vicore Pharma Holding AB's highest PS Ratio was 36583.78. The lowest was 7.47. And the median was 1171.04.

VCRE's PS Ratio is ranked worse than
95.69% of 929 companies
in the Biotechnology industry
Industry Median: 9.64 vs VCRE: 891.58

Vicore Pharma Holding AB's Revenue per Sharefor the three months ended in Mar. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.

During the past 12 months, the average Revenue per Share Growth Rate of Vicore Pharma Holding AB was -51.70% per year.

During the past 13 years, Vicore Pharma Holding AB's highest 3-Year average Revenue per Share Growth Rate was 2.00% per year. The lowest was -27.60% per year. And the median was -12.80% per year.

Back to Basics: PS Ratio


Vicore Pharma Holding AB  (NAS:VCRE) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Vicore Pharma Holding AB PS Ratio Related Terms


Vicore Pharma Holding AB PS Ratio Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB PS Ratio Chart

Vicore Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 10.58 706.25

Vicore Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 243.10 211.39 342.05 706.25 714.29

VCRE vs : PS Ratio Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's PS Ratio distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's PS Ratio falls into.


VCRE
13GF Score
Vicore Pharma Holding AB VCRE
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Vicore Pharma Holding AB's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=15.025/0.001
=

Vicore Pharma Holding AB's Share Price of today is $15.025.
Vicore Pharma Holding AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Vicore Pharma Holding AB Business Description

Comparable Companies
Other Exchanges VICO:Sweden6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score

Get the complete analysis for VCRE

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.03
Price